Exploring the role of the Mediterranean diet in mitigating gestational diabetes risk
A recent comprehensive study published in the journal Nutrition & Diabetes delves into the potential impact of the Mediterranean diet (MedDiet) on reducing the incidence of gestational diabetes mellitus (GDM), a prevalent complication during pregnancy characterised by impaired insulin utilisation due to placental hormones.
GDM not only poses immediate health risks to both mother and child during pregnancy, including heightened risk of birth complications and future chronic conditions, but also contributes to longer-term health issues. Consequently, managing blood glucose levels through medical and dietary measures is essential.
Prevailing research underscores the efficacy of dietary and lifestyle changes in the early stages of pregnancy, or even prior, in averting GDM. Diets high in saturated fats, cholesterol, carbohydrates, and total fats are typically linked to a higher GDM risk.
The Mediterranean diet is noted for its emphasis on whole grains, vegetables, legumes, and foods high in monounsaturated fatty acids (MUFAs), while limiting processed and red meats. Instead of isolating individual dietary components, assessing overall dietary patterns like the MedDiet may offer a holistic approach to managing or preventing GDM.
Numerous studies corroborate that a strict adherence to the MedDiet correlates with a reduced risk of GDM. However, a systematic review and meta-analysis are crucial to consolidate these findings comprehensively.
The current review collated studies up to August 2023 from databases such as PubMed, Web of Science, Google Scholar, and Scopus, excluding duplicates, animal studies, ecological studies, short communications, and non-English articles.
From the selected studies—two case-control and eight cohort studies—conducted in diverse locations including the USA, various Mediterranean countries, Australia, Iran, Spain, and Greece, researchers analysed data from over 32 million participants aged 18 to 45.
The Mediterranean Diet Adherence Screener (MEDAS) score, higher quartiles of alternate MED (AMED) score, and the Mediterranean-Style Dietary Pattern Score (MSDPS) were tools used to assess dietary adherence. GDM outcomes were evaluated using criteria from the National Diabetes Data Group, and through fasting or postprandial blood sugar levels, or glucose challenge tests.
Findings from seven out of ten studies reviewed demonstrated a significant link between higher MedDiet adherence and lower GDM risk, although results varied due to differences in study designs or dietary assessment periods.
Interestingly, while case-control studies reported a substantial 75% reduction in GDM risk among women with higher MedDiet adherence, cohort studies indicated a more moderate 20% risk reduction. The larger reductions noted in case-control studies might stem from recall biases, possibly exaggerating the risk reduction.
Subgroup analyses showed that the benefits of MedDiet adherence in reducing GDM risk applied across both Mediterranean and non-Mediterranean populations, suggesting universal applicability of this dietary pattern.
Higher consumption of whole grains, fruits, vegetables, extra virgin olive oil, nuts, and legumes, alongside regular fish and seafood intake, characterises greater adherence to the MedDiet. This diet, rich in antioxidants and vitamins, mitigates oxidative stress and inflammation, critical factors in chronic disease progression.
The diet’s high polyphenol content in fruits and vegetables plays multiple roles in reducing GDM risk, including glucose absorption inhibition in the gastrointestinal tract, anti-inflammatory properties, microbiota modification, and enhanced antioxidant capacity.
Previous meta-analyses have linked greater MedDiet adherence to reduced obesity or overweight risks by 9%, noting that obesity and insulin resistance are significant GDM risk factors. Additionally, whole grains and nuts, rich in MUFAs and polyunsaturated fatty acids (PUFAs), help regulate blood glucose levels and control appetite.
Observational studies have suggested that long-term red meat consumption may increase GDM risk, further supporting the reduced GDM incidence among those adhering to the MedDiet.
The current systematic review and meta-analysis provide strong evidence supporting the MedDiet’s role in reducing GDM risk when followed before or during pregnancy. It is advisable for women of reproductive age to consider the MedDiet to prevent GDM and other adverse pregnancy outcomes.
Further research should explore the interaction between the MedDiet, genetic factors, and lifestyle elements to refine preventive strategies for GDM.
Read More
Alarming surge in severe obesity among adolescents in Ireland
Since 2018, Ireland has witnessed a tenfold increase in referrals of adolescents to specialised obesity clinics, highlighting a critical and worsening health issue among young people. Dr. Órla Walsh, a paediatric specialist at Children’s Health Ireland in Temple Street, has expressed deep concern over the rising number of young patients exhibiting severe symptoms of obesity. Over the past six years, the situation has escalated, with Dr. Walsh noting the overwhelming demand for treatment at her medically-led complex obesity clinic. “I’m running a clinic that is merely the tip of the iceberg. It is a tertiary clinic, which means we only see cases of severe complex obesity that also present with at least two other complications. Since its inception last year, our waiting list has grown to include 419 children,” Dr. Walsh explains.
The pervasive influence of obesity on both the physical and psychological well-being of children is profound. Dr. Walsh stresses that neither the child nor their family is at fault, pointing to genetic factors and an environment that promotes obesity. “The relentless marketing by food and beverage companies significantly contributes to the problem. Our children are inundated with advertisements daily, pushing fast food, processed items, and oversized portions,” she remarks.
A study presented in Dublin last year offered a glimmer of hope, showing promising results from weekly weight loss injections of semaglutide, a medication under the brand names Wegovy and Ozempic. Nearly half of the children treated no longer met the criteria for clinical obesity following the treatment. However, access to such medications is restricted; adolescents can only use these drugs if they are diabetic or if they can afford private treatment, costing approximately £200 a month.
Dr. Walsh highlights the inequality in access to treatment, especially among socioeconomically disadvantaged adolescents. She contrasts the situation in Ireland with international standards where adolescents have access to weight loss medications and bariatric surgery, which are not readily available in Ireland. Efforts have been made to urge the Health Service Executive (HSE) to provide weight loss medication freely to children suffering from complex obesity. “Treating these adolescents can prevent complications later in life. Investing in adolescent health yields a triple benefit: improving their current and future health, and potentially the health of their future children,” Dr. Walsh advocates.
The paediatrician also runs a general adolescent clinic and sees a troubling trend of obesity-related medical complications such as hypertension, pre-diabetes, and obstructive sleep apnoea, along with significant psychiatric comorbidities. “The stigma, shame, and bullying associated with obesity severely affect their mental health, leading to anxiety, depression, and often undiagnosed eating disorders,” she reveals.
Further stressing the urgency, a 2022 international report indicated that Ireland had the highest rate of risk factors for non-communicable diseases in European adolescents. The study surveyed nearly 500,000 children aged between 11 and 17, revealing that 63% of Irish adolescents exhibited four or more risk factors such as physical inactivity, poor diet, and substance use, compared to just 13% of their Swedish counterparts.
Dr. Walsh reflects on her recent observations in Sweden, where a healthier environment for children starkly contrasts with the situation in Ireland. “Sweden offers extensive support for child health, including widespread access to playgrounds, pools, and government-supported child care, which contributes to a healthier societal setup,” she notes.
The article concludes with the HSE’s response on the current status of obesity treatments under consideration for reimbursement, including medications like Saxenda and Wegovy, which are aimed at adults and potentially extendable to adolescents.
Dr. Walsh’s observations and the data presented underscore a dire need for systemic change to combat adolescent obesity in Ireland, a public health challenge that has only intensified in the wake of the global pandemic.
Read More
New study finds financial rewards enhance obesity interventions for teens
A recent study has demonstrated that adolescents suffering from severe obesity achieve a more significant reduction in body mass index (BMI) when meal-replacement therapy is supplemented with financial incentives, as opposed to meal-replacement therapy alone. These findings have been documented in an article published by JAMA Pediatrics.
Justin Ryder, PhD, an associate professor involved in both the Surgery Division of Pediatric Surgery and Pediatrics, collaborated on this research. Ryder highlighted the importance of developing more effective treatments for severe obesity, which currently impacts approximately 20% of children and adolescents in the U.S. The Centers for Disease Control and Prevention defines severe obesity as having a BMI at or above the 95th percentile for one’s age and gender. This condition predisposes individuals to a host of future health issues including adult obesity, cardiovascular diseases, and type two diabetes.
Previous studies have shown that meal replacement therapy (MRT), which replaces regular meals with controlled, pre-portioned meals totalling 1,200 calories per day, tends to be more effective than traditional lifestyle changes for reducing BMI in young people with severe obesity. In light of these findings, the recent study aimed to assess whether the addition of financial incentives would enhance the effectiveness of MRT.
“There’s literature for adults that supports that tying in financial incentives to weight loss or physical activity programs increases adherence, and so we wanted to see whether or not adding financial incentives to a behavioural/nutrition weight loss program using meal replacement therapy would increase adherence and through adherence, increase the efficacy of the treatment,” explained Ryder.
The research involved 126 adolescents, divided into two groups of 63 participants each. For one year, one group received MRT along with financial incentives based on their weight reduction from baseline, while the other group received only the MRT. At the end of the 52-week period, the group that received both MRT and financial incentives exhibited a greater decrease in BMI—by 6 percentage points—and a higher reduction in total body fat mass—4.8 kilograms compared to their counterparts who only received MRT.
Ryder added, “Using a cost-effectiveness analysis, we looked at mean fat mass lost between the two treatments and found that despite providing the additional meal replacements for per pound lost, it was cost-effective to do so.”
The study’s authors also noted the need for the development of interventions that maintain effectiveness beyond a one-year timeframe. “While financial incentives plus MRT appears to be a longer-term strategy than MRT alone, treatment withdrawal will likely result in BMI increase. As such, research is needed to identify strategies that are scalable and feasible in the long term given the chronic nature of obesity,” they mentioned.
This pivotal research was funded by multiple grants from the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institutes of Health National Center for Advancing Translational Sciences. Financial support for the meal programs was provided by Healthy For Life Meals, contributing to the resources necessary for this comprehensive study.
Read More
Significant weight loss improves metabolism, mood, and decision-making in individuals with obesity
Severe obesity not only predisposes individuals to a variety of health risks but also significantly alters their metabolic functions and psychological states. Historically, it was believed that individuals with severe obesity tended to display heightened impulsivity and a greater propensity for risk-taking. However, recent research conducted by scientists at the DZD partner German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE) has explored whether substantial weight loss could reverse these effects, enhancing both metabolic and psychological conditions and thereby improving decision-making processes. These findings have been elucidated in the publication ‘Clinical Nutrition‘.
Human behaviour is influenced by a myriad of factors including personality traits and internal physiological signals like glucose metabolism and mood states. In individuals with obesity, these internal signals are often disrupted, leading to unreliable decision-making foundations. Beatrix Keweloh, a doctoral researcher in the Department of Neuroscience of Decision and Nutrition, spearheaded an intervention study to investigate if these impairments could be reversed through significant weight loss. The study involved 62 participants, aged 18 to 75, all with severe obesity (BMI > 35 kg/m2). They underwent a rigorous 10-week diet limiting their daily caloric intake to 800 kilocalories.
Measurements of participants’ weight, body fat, mood (via a questionnaire), and risk-taking tendencies (using a computer-based test) were taken at both the start and conclusion of the diet. Results demonstrated a considerable decrease in BMI and HbA1c levels—markers of glucose metabolism—and notable improvements in mood. Additionally, there was a shift towards more risk-averse behaviours, suggesting a direct correlation between BMI and risk behaviour in individuals with obesity. “Our findings also indicated that the metabolic factor HbA1c becomes a predominant predictor of risk-taking behaviours post-weight loss,” commented Beatrix Keweloh.
The study further noted that post-weight loss, mood had a diminished impact on decision-making, with metabolic signals becoming the primary influencers of risk behaviour. “Weight loss positively impacts glucose metabolism and mood, and importantly, restores the regulatory function of glucose metabolism in decision-making processes,” Keweloh summarised.
The interplay between weight loss and the metabolic and psychological factors influencing risk-taking is intricate, with BMI playing a pivotal role. A reduced propensity for risk-taking correlates with a healthier lifestyle, crucial for both achieving and maintaining a healthy body weight. Consequently, interventions aimed at managing weight should incorporate both metabolic and psychological considerations to prevent relapses and foster metabolically driven decisions.
“This study is pioneering as it considers both metabolic and psychological aspects in overweight individuals,” stated Prof. Soyoung Q Park, head of the Department of Neuroscience of Decision and Nutrition. “It marks a significant contribution to the field, although it also highlights the necessity for further research to fully comprehend how energy balance and psychological factors influence our choices.”
Globally, the prevalence of obesity is escalating rapidly. According to a report in the British journal ‘Lancet’, over one billion individuals are affected worldwide, out of a global population of approximately eight billion. Data from the Federal Statistical Office reveal that in Germany alone, around 42 percent of women and 62 percent of men are considered to have either overweight or obesity. The World Health Organization (WHO) classifies individuals with a BMI over 25 as having overweight and over 30 as having obesity.
In studies assessing risk-taking tendencies, various methodologies are employed, such as computerised lottery tasks. In this particular study, a conventional lottery task was utilised where participants made choices between a guaranteed monetary amount and a variable amount, with a 50 percent chance of winning in each scenario.
Read More
New clinic for childhood obesity to open in Surrey, UK
Surrey is set to benefit from a pioneering initiative aimed at combating childhood obesity, as revealed by the BBC. The newly established Complications from Excess Weight (CEW) clinic, a part of Ashford and St Peter’s Hospitals NHS Foundation Trust, is preparing to welcome its first referrals in early autumn, 2024.
This service forms part of a broader national strategy, initiated by NHS England in 2022, to open 30 dedicated clinics across the country. These clinics are designed to offer comprehensive support services, including mental health care and nutritional guidance, to children grappling with obesity.
The teams at these clinics will consist of multidisciplinary professionals such as consultant paediatricians, dietitians, and psychologists, who are committed to a holistic treatment approach for the affected children and their families.
Vicky Williams, the Associate Director of Women and Children’s Services at Surrey Heartlands Integrated Care System, highlighted the urgent need for such services: “Obesity affects one in four children in the UK and it can increase the likelihood of a child developing serious health issues.” She emphasised the importance of early intervention and continuous support to prevent future complications. Williams expressed optimism about the local availability of the service, stating, “It means that, in future, children and young people will be referred to a specialist service in Surrey, closer to home, instead of having to travel further away – so it’s good news for families in Surrey.”
Furthermore, the NHS Frimley Integrated Care Board mentioned that currently, children eligible for the CEW clinic’s services in its area are receiving care from consultants based in Southampton. Plans are underway to establish a similar clinic closer to home for patients from Surrey Heath and Farnham, North East Hampshire, and East Berkshire.
The urgent need for such clinics is underscored by alarming statistics; NHS leaders have noted that obesity impacts one in four children in the UK, potentially leading to severe health problems such as Type 2 diabetes, liver disorders, and early onset heart disease. Data from the latest child measurement programme in schools indicates that nearly 13% of children assessed in Surrey during the 2022/23 school year were living with obesity by the time they reached year six of primary school.
Previous governmental measures include the 2018 imposition of a tax on high-sugar soft drinks and limitations on the promotion of unhealthy products in supermarkets across England.
The new Labour government has expressed a firm commitment to addressing this health crisis. A Department for Health and Social Care spokesperson detailed forthcoming measures: “We will introduce tight restrictions on advertising junk food, alongside banning children from being able to purchase sugary, high caffeine energy drinks. By building a healthier society, we will help to build a healthy economy.” This statement underscores the government’s proactive stance on cultivating a healthier future for the next generation.
Read More
Examining the impact of excess weight on semen quality
A recent systematic review and meta-analysis published in the International Journal of Obesity, conducted by researchers in China, has revealed the profound impacts of obesity and overweight on male fertility. This study delves into the association between Body Mass Index (BMI) and semen quality, indicating significant adverse effects, particularly in men with more severe levels of obesity.
Approximately 15% of couples of reproductive age worldwide face infertility issues, with male factors, notably poor semen quality, contributing to 20–70% of these cases. Over recent decades, a marked decline in semen quality has been noted globally. For instance, significant decreases in total sperm count and sperm concentration were observed from 1973 to 2011 in Western nations, and from 1981 to 2019 in China. This decline is influenced by various factors including age, lifestyle, and environmental conditions. An increase in abnormal BMI has been pinpointed as a potential risk factor amidst these changes. Previous studies have linked obesity to reductions in semen quality, but results have varied due to differences in BMI classifications and other methodological limitations.
To address these inconsistencies and provide clearer insights, the researchers included data from 50 human studies, involving a total of 71,337 men aged between 26 and 44 years. These studies were sourced from Embase, PubMed, and Web of Science and categorised men based on their BMI: under 25.0 kg/m² as the reference group, 25.0–29.9 kg/m² as overweight, and over 30.0 kg/m² as having obesity. The studies examined various semen parameters such as volume, sperm concentration, motility, total sperm count, and morphology. Men were also categorised based on their fertility status into general, infertile or sub-fertile, and suspiciously sub-fertile groups.
The analysis, employing statistical tools like the random effects model, Cochran’s Q tests, and I² statistics, demonstrated that obesity was associated with significant reductions in several key semen parameters. Men with obesity, for instance, showed reductions of 0.24 ml in semen volume, 19.56 × 10⁶ in total sperm number, and decreases in both total and progressive motility. Men with overweight experienced milder declines, which were not as widespread across different semen parameters.
The study also highlighted that the detrimental effects of obesity on semen quality varied across different global regions, including America, Asia, and Europe, suggesting regional differences in lifestyle and environmental factors could influence the degree of impact. Furthermore, the findings were consistent across different methods of semen assessment, reinforcing the robustness of the results.
Despite its strengths, such as a large sample size and unified BMI classifications, the study faced limitations related to potential inaccuracies in aggregated data and the BMI’s inability to distinguish between muscle and fat mass. Additionally, the traditional semen parameters used might not fully reflect the functional capacity of sperm.
In conclusion, the analysis confirmed a significant association between higher BMI and poorer semen quality, with more severe impacts observed in men with higher obesity classes. These findings emphasise the importance of maintaining a healthy weight to support male reproductive health and suggest that future studies should explore broader reproductive implications of obesity using more comprehensive indicators of sperm health and function.
Read More
Nutritional studies highlight pulses as key to lowering diabetes and cholesterol risks
Research consistently highlights pulses—such as beans, peas, lentils, and chickpeas—as crucial allies in the fight against diabetes and elevated cholesterol levels. This insight comes at a critical time, as projections from a study published in The Lancet last year forecast that diabetes could affect over 1.31 billion people globally by 2050. Concurrently, elevated cholesterol levels remain a significant health issue, with nearly half of adults in the UK exceeding national guidelines.
A detailed review in the journal Nutrients has shown that regular consumption of pulses can significantly improve these concerning health trends. The review meticulously examined thirty studies that looked at various types of pulses, including lentils, chickpeas, and several common beans like pinto, black, and kidney beans. The studies covered a wide array of health outcomes, from lipid profiles and blood pressure to risks of cardiovascular diseases and diabetes management.
The findings from these studies are telling. They specifically note improvements in low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, systolic and diastolic blood pressure, fasting blood sugar, haemoglobin A1c levels, waist circumference, and markers of inflammation and sensitivity such as C-reactive protein. These outcomes particularly underscore the potential of pulses to enhance lipid profiles and manage blood pressure.
The review emphasised that interventional studies, which typically have larger sample sizes and provide robust data, consistently confirm the health benefits of pulses. These studies often involved dietary adjustments where pulses replaced red meat or were added to diets as fixed servings. The results repeatedly demonstrated improvements in dietary quality and beneficial health outcomes.
Pulses’ potential to prevent heart disease is particularly noteworthy, largely due to their ability to lower total and LDL cholesterol levels. The authors of the review highlight that pulses are low in fat and rich in healthy mono- and polyunsaturated fats, essential micronutrients, and bioactive compounds with antioxidant properties, making them a true “nutritional powerhouse.”
Longitudinal studies also link higher pulse consumption with reduced risks of developing type 2 diabetes. This association is bolstered by interventional studies that document notable improvements in fasting glucose levels and insulin sensitivity with increased pulse intake. Consequently, pulses are not only pivotal in preventing diabetes but also in managing blood glucose levels effectively.
Tim McGreevy, CEO of USA Pulses, commented on the research, stating, “This research accentuates the fact that pulses are beneficial for health in so many ways, underscoring dietary guidelines that endorse plant-based eating patterns,” even though he was not directly involved in the study.
Additionally, awareness about type 2 diabetes is critical as many individuals may be unknowingly afflicted. Symptoms to watch for include increased urination, persistent thirst, excessive tiredness, unexplained weight loss, genital itching or recurrent thrush, delayed healing of wounds, and blurred vision. Recognising these signs can prompt earlier intervention and management of the condition, further reducing long-term health risks.
Read More
Lifestyle changes in mothers with obesity could mitigate heart risks in offspring
Researchers at King’s College London have discovered that lifestyle modifications could potentially reduce the risk of children developing certain cardiovascular diseases, which are believed to stem from maternal obesity and related foetal heart abnormalities.
Globally, obesity rates among pregnant women are on the rise, with more than half of the women attending antenatal clinics in England and Wales either having overweight (28.5%) or obesity (22.7%). Studies have increasingly shown that obesity during pregnancy can precipitate cardiovascular complications and disrupt normal cardiac development in the offspring.
The findings were detailed in a recent publication in the International Journal of Obesity, led by Dr Samuel Burden. The research team conducted a systematic review of existing studies to explore whether interventions targeting obesity in pregnant women—through diet, exercise, and other physical activities—can foster cardiac health in their children.
The selection criteria for the studies included randomised trials focusing on lifestyle changes among pregnant women diagnosed with obesity. The evidence reviewed indicated that such interventions could avert atypical cardiac development in children, highlighting several benefits commonly associated with improved heart health, such as decreased thickening of the heart walls, maintaining normal heart weight, and reducing the likelihood of increased heart rates.
Dr Samuel Burden commented, “We and others have demonstrated that maternal obesity correlates with signs of poor heart development in children. Our review of existing literature on dietary and exercise interventions in women with obesity, either before or during pregnancy, revealed that these measures indeed offer a protective shield against the extent of this unhealthy heart development in children. Should these results hold into adulthood, these interventions could shield against the detrimental cardiovascular conditions seen in adult children of mothers with obesity, thus guiding public health strategies to enhance cardiovascular health for future generations.”
Although the data supports the premise that lifestyle adjustments in pregnant women with obesity may safeguard infant cardiovascular health, further comprehensive studies are necessary. These should involve larger cohorts and extend into later childhood to affirm the findings and assess if the benefits continue into adulthood.
Should future research corroborate these findings, the implications could be significant, potentially shaping public health initiatives aimed at improving heart health across generations.
Read More
Beyond BMI: A new framework for diagnosing obesity with a focus on overall health
The traditional method of diagnosing and managing obesity, which heavily relies on body mass index (BMI), is increasingly seen as inadequate. Acknowledging this, the European Association for the Study of Obesity (EASO) has introduced a comprehensive new framework for diagnosing, staging, and managing adult obesity. Detailed in a recent publication in Nature Medicine, this framework aims to incorporate the latest scientific insights and advancements, including novel obesity medications, to ensure more effective and inclusive treatment strategies.
Obesity is widely recognised as a multifactorial, chronic, relapsing, non-communicable disease characterised by an abnormal and/or excessive accumulation of body fat. Traditionally, the diagnosis has been predominantly based on BMI cut-off values. This method fails to consider critical factors such as the distribution and functional roles of adipose tissue in the disease’s severity.
The EASO Steering Group, comprising current and former association presidents among other experts, has crafted a series of statements that update the obesity management approach to reflect the latest scientific knowledge. A key update in this new framework is the revised approach to the anthropometric component of obesity diagnosis. The authors explain, “An important novelty of our framework regards the anthropometric component of the diagnosis. The basis for this change is the recognition that BMI alone is insufficient as a diagnostic criterion, and that body fat distribution has a substantial effect on health.” They specifically highlight the health risks associated with the accumulation of abdominal fat, noting its association with an increased risk of cardiometabolic complications and its significance as a determinant of disease, even in individuals with a BMI below traditional obesity thresholds.
The new framework underscores the importance of considering abdominal (visceral) fat accumulation as a critical health risk factor, even in individuals with lower BMI (≥25–30 kg/m^2) who exhibit significant abdominal fat but may lack overt clinical symptoms. This broader definition aims to reduce the risk of undertreating these individuals compared to the current BMI-based criteria.
Treatment recommendations within the framework align with existing guidelines but emphasise behavioural changes such as dietary adjustments, increased physical activity, stress management, and improved sleep quality. Psychological therapy, obesity medications, and metabolic or bariatric procedures are also considered crucial, depending on individual needs.
The steering committee has pointed out that the traditional reliance on BMI cut-offs in clinical trials and guidelines often excludes individuals who, despite having a lower BMI, carry a significant obesity-related health burden. The committee suggests a shift towards including patients with a BMI of at least 25 kg/m^2 and a waist-to-height ratio above 0.5, who also exhibit medical, functional, or psychological impairments, in obesity medication and treatment programmes.
The authors make a call to action to pharmaceutical companies and regulatory bodies: “This statement may also be seen as a call to pharmacological companies and regulatory authorities to use inclusion criteria that are more adherent to the clinical staging of obesity and less to traditional BMI cut-offs when designing future clinical trials with obesity medications.”
In conclusion, the authors advocate for a paradigm shift in obesity management, likening it to the management of other chronic non-communicable diseases. They emphasise the importance of defining long-term, personalised therapeutic goals from the outset of treatment, considering the disease’s stage and severity, therapeutic options, side effects, patient preferences, and individual challenges. They stress the necessity for a comprehensive, life-long treatment plan over mere short-term weight reduction, stating, “Emphasis on the need for a long-term or life-long comprehensive treatment plan rather than short-term body weight reduction is warranted.”
Read More
Research highlights how lifestyle can overcome genetic obesity risks
A groundbreaking study published in “Cell Metabolism” has illuminated the powerful role of lifestyle modifications in mitigating the genetic predisposition to obesity, revealing new avenues for managing this global health challenge.
Obesity has reached pandemic proportions, exacerbated by inactive lifestyles and the consumption of high-calorie diets. The condition is influenced by both heritable and polygenic factors, with numerous metabolic pathways and over a thousand genetic variants playing roles. Traditionally, it was assumed that one’s genetic risk for obesity was unalterable.
Recent gene-environment studies have hinted that certain lifestyle choices might lessen the influence of specific genes linked to obesity. These studies, however, typically focused only on limited genes and lifestyle factors, leaving a gap in understanding the broader interaction between lifestyle habits and genetic predispositions.
This latest research delved into whether lifestyle changes could indeed counteract genetic risks. The study cohort included 338,600 white British participants from the UK Biobank, refined to 337,554 after excluding those lacking essential data. Researchers calculated a polygenic score (PGS) from a genome-wide association study on body mass index (BMI) specific to individuals of European descent. They also developed a healthy lifestyle score based on five factors: alcohol consumption, sleep duration, sedentary behaviour, diet, and physical activity. The study’s primary focus was on new obesity cases, with existing obesity cases as a secondary focus.
The researchers predicted absolute risks using odds ratios (ORs) and hazard ratios (HRs) for both new and existing obesity, relative to PGS percentile and lifestyle factors. These ratios were derived from Cox proportional hazard and logistic regression models. They also calculated the probability of developing obesity by age 75 and identified new obesity-related morbidities (ORMs) from various health data sources.
Analyses showed that high genetic risk and unhealthy lifestyle habits were each linked to higher obesity risks, both independently and combined. The risk was most pronounced in those with both high genetic predisposition and poor lifestyle habits, with a HR of 3.54 compared to those with low genetic risk and healthy lifestyles.
Interestingly, the median likelihood of obesity by age 75 varied significantly with lifestyle: 2.8% in those with poor lifestyles versus 1.7% in those with healthier choices. This pattern was echoed in the analysis of existing obesity cases.
The study also found significant additive interactions between lifestyle and genetic risk in terms of obesity incidence, with consistent results from multiplicative interaction analysis. Importantly, sedentary behaviour was linked to the highest obesity risk, regardless of genetic background. Conversely, individuals with high genetic risk but who maintained healthy lifestyles had similar ORMs to those with lower genetic risk.
Overall, the study underscores the profound impact of healthy lifestyle choices in reducing the risk of obesity and its related health issues, even among those with a high genetic predisposition. These findings advocate for the promotion of active, health-conscious behaviours across all genetic backgrounds as a critical strategy in combating obesity.
This research not only challenges the fatalistic view of genetic determinism but also highlights the empowering role of personal lifestyle choices in managing one’s health.
Read More
New research highlights the obesity-fighting properties of the ketogenic diet
A groundbreaking study recently published in Nature Metabolism has uncovered the protective effects of bile acids (BAs) induced by the ketogenic diet (KD) in the fight against obesity.
Obesity is linked to a myriad of health issues including cardiovascular diseases, cancer, diabetes, and non-alcoholic fatty liver disease. These associations underscore the urgent need for effective treatments to alleviate its extensive health impacts.
The ketogenic diet, recognised for its distinctive metabolic effects, has been proven beneficial in managing refractory epilepsy and other health disorders. Research indicates that changes in gut microbiota and metabolites might play a role in the diet’s protective properties against intestinal inflammation and seizures.
Although it’s clear that gut microbiota and metabolites are pivotal in the metabolic transformations elicited by KD in both rodents and humans, the specific microbes and metabolites responsible remain unidentified.
In the referenced study, the efficacy of KD in obesity prevention was demonstrated through an experimental setup involving mice. These mice were fed either a standard chow diet (CD) or a KD for seven weeks. Results indicated significant reductions in fasting glucose levels and body weight in those on KD. Metabolomics analysis further identified shifts in the metabolic profiles of the KD group, with increases in 22 metabolites and decreases in 18.
A subsequent experiment involved feeding mice with CD, KD, or a methionine-supplemented version of KD (KDM) over seven weeks. The addition of methionine to KD reversed the diet’s reductions in glucose levels and body weight and decreased six taurine-conjugated bile acids in serum. KD alone reduced levels of certain unconjugated BAs, which were restored by KDM.
When gut microbiota were depleted, differences in body weight and glucose levels between KD and KDM groups vanished, highlighting the role of microbiota in these effects. Faecal microbiota transplantation (FMT) from KD-fed to CD-fed mice resulted in weight loss and enhanced glucose tolerance. Conversely, FMT from KDM mice had no significant impact.
Further analyses showed that KD reduced the alpha diversity of gut microbiota, a change reversed by KDM. This diet also affected specific bacterial strains, which were restored by KDM supplementation. Studies on energy absorption revealed that KD-fed mice exhibited higher faecal energy content, suggesting a reduction in calorie absorption.
RNA sequencing of ileal tissues indicated that treatment with specific bile acids (TUDCA or TDCA) downregulated CAR1, a gene associated with obesity. These treatments also diminished lipid accumulation in cells, facilitated weight loss, and decreased intestinal lipid absorption in mice.
In models of diabetes and obesity, treatments with TUDCA and TDCA resulted in weight reduction, lower fasting glucose levels, improved glucose tolerance, and decreased liver fat. Human studies paralleled these findings, showing that lower plasma levels of certain conjugated BAs were associated with higher body mass index and fasting glucose levels.
In conclusion, this study illuminates the potential of the ketogenic diet and targeted bile acid treatments in managing obesity and improving metabolic health through modifications in gut microbiota and metabolic processes.
The findings highlight critical host-gut microbiota interactions and support the use of TUDCA and TDCA as potential therapeutic agents for tackling obesity and its associated complications.
Read More
Natural compound found in olives shown to lower blood sugar and aid weight loss, mouse study shows
A novel study conducted using mice models has highlighted the potential of elenolic acid, a natural compound extracted from olives, in mitigating obesity and type 2 diabetes. This groundbreaking research suggests that elenolic acid could serve as a basis for the development of affordable, safe natural products aimed at managing these prevalent health issues.
In a series of experiments, diabetic mice with obesity administered with elenolic acid orally displayed a significant reduction in body weight and enhanced glucose regulation within just one week. These results were noteworthy when compared to a control group of mice with obesity that did not receive the treatment. Remarkably, the glucose-lowering impact of elenolic acid was on par with liraglutide, an injectable diabetes medication, and surpassed the effectiveness of metformin, a commonly used oral diabetes drug.
Professor Dongmin Liu, the lead researcher and a professor at the Department of Human Nutrition, Foods and Exercise at Virginia Tech, explained the motivation behind their focus on natural compounds. “Lifestyle modifications and public health measures have had limited impact on the rising prevalence of obesity, one of the top risk factors for type 2 diabetes. Available obesity drugs are ineffective in weight loss maintenance, expensive and/or carry potential long-term safety risks. Our goal was to develop safer, cheaper and more convenient multi-targeting agents that can prevent the occurrence of metabolic disorders and type 2 diabetes,” stated Liu.
The research findings will be presented by Dr. Hana Alkhalidy, a scientist in Liu’s laboratory, at NUTRITION 2024, the premier annual event of the American Society for Nutrition.
The team at Virginia Tech has previously investigated various natural compounds targeting molecular aspects of metabolism in critical body parts like the pancreas, muscle, fat tissues, and liver. Their latest strategy focuses on stimulating hormone secretion in the gut, a method that could indirectly improve metabolic functions due to natural products’ generally poor bioavailability.
Their screening identified that elenolic acid, found abundantly in mature olives and extra virgin olive oil, stimulates the release of metabolic hormones GLP-1 and PYY in the gut. These hormones are integral during meals, enhancing satiety and regulating blood sugar and metabolism. The researchers synthesized elenolic acid from its precursor, oleuropein, which proved to be a cost-effective method compared to direct extraction from olives.
Further testing revealed that diabetic mice with obesity treated with elenolic acid for four to five weeks showed a 10.7% reduction in obesity and exhibited glucose levels and insulin sensitivity comparable to healthy, lean mice. Additionally, the treatment significantly curbed food intake and fostered weight loss, effects associated with increased levels of PYY and GLP-1 and decreased expression of agouti-related peptide, a hypothalamic peptide that promotes overeating and weight gain when overexpressed.
“Overall, the study showed that elenolic acid from olives has promising effects on hormone release and metabolic health, particularly in obese and diabetic conditions,” Liu remarked. He noted that the compound mimics the physiological conditions of eating to enhance gut metabolic hormone secretion, thereby helping to regulate energy balance and metabolic health.
Despite these promising results, the researchers cautioned that the concentration of elenolic acid in typical olive products is quite low, implying that the health benefits observed in the study are unlikely to be replicated through consumption of olives and olive oil alone.
The research team is now focused on elucidating the metabolic pathway of elenolic acid, from its absorption to its excretion. This exploration will provide further insights into the compound’s efficacy and safety, paving the way for potential clinical trials.
Read More